PRADAXA (dabigatran etexilate mesylate)
ORAL ANTICOAGULANTS · PULMONARY THROMBOEMBOLISM ·+4
Boehringer Ingelheim
Drug class
Oral Anticoagulants
Oral anticoagulants are a major therapeutic class of systemically absorbed antithrombotic medications administered orally to prevent and treat pathological blood clot formation. Read more about Oral Anticoagulants
61 drugs in this class 38 manufacturers
Drugs in Oral Anticoagulants
XARELTO (rivaroxaban)
ORAL ANTICOAGULANTS · PULMONARY THROMBOEMBOLISM ·+8
JANSSEN PHARM.
WARFARIN SODIUM
ORAL ANTICOAGULANTS · MYOCARDIAL REINFARCTION PREVENTION ·+12
TARO PHARM USA
ELIQUIS (apixaban)
ORAL ANTICOAGULANTS · PULMONARY THROMBOEMBOLISM ·+5
BMS PRIMARYCARE
JANTOVEN (warfarin sodium)
ORAL ANTICOAGULANTS · MYOCARDIAL REINFARCTION PREVENTION ·+12
Upsher-Smith Laboratories
XARELTO (rivaroxaban)
ORAL ANTICOAGULANTS · PULMONARY THROMBOEMBOLISM ·+8
JANSSEN PHARM.
SAVAYSA (edoxaban tosylate)
ORAL ANTICOAGULANTS · PULMONARY THROMBOEMBOLISM ·+2
DAIICHI SANKYO,
WARFARIN SODIUM
ORAL ANTICOAGULANTS · MYOCARDIAL REINFARCTION PREVENTION ·+12
EXELAN PHARMACE
ELIQUIS (apixaban)
ORAL ANTICOAGULANTS · PULMONARY THROMBOEMBOLISM ·+5
BMS PRIMARYCARE
Filter & compare in the drug finder →
Opens the drug finder with Oral Anticoagulants preselected. Add indication or manufacturer filters there.
Oral anticoagulants are a major therapeutic class of systemically absorbed antithrombotic medications administered orally to prevent and treat pathological blood clot formation.
They function by inhibiting critical components of the coagulation cascade, primarily through vitamin K antagonism to block clotting factor synthesis or via direct targeted inhibition of specific clotting enzymes such as factor Xa or thrombin.
Clinically, these agents are indicated for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, managing and preventing venous thromboembolism—including deep vein thrombosis and pulmonary embolism—and providing thromboprophylaxis in select cardiovascular and orthopedic settings.
-
nih.gov
Oral anticoagulants are a major therapeutic class of systemically absorbed antithrombotic medications administered orally to prevent and treat pathological blood clot formation
-
nih.gov
They function by inhibiting critical components of the coagulation cascade, primarily through vitamin K antagonism to block clotting factor synthesis or via direct targeted inhibition of specific clotting enzymes such as factor Xa or thrombin
-
nih.gov
They function by inhibiting critical components of the coagulation cascade, primarily through vitamin K antagonism to block clotting factor synthesis or via direct targeted inhibition of specific clotting enzymes such as factor Xa or thrombin
-
nv.gov
Clinically, these agents are indicated for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, managing and preventing venous thromboembolism—including deep vein thrombosis and pulmonary embolism—and providing thromboprophylaxis in select cardiovascular and orthopedic settings
-
nih.gov
Clinically, these agents are indicated for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, managing and preventing venous thromboembolism—including deep vein thrombosis and pulmonary embolism—and providing thromboprophylaxis in select cardiovascular and orthopedic settings
-
nih.gov
Clinically, these agents are indicated for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, managing and preventing venous thromboembolism—including deep vein thrombosis and pulmonary embolism—and providing thromboprophylaxis in select cardiovascular and orthopedic settings
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.